Edition:
United States

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

33.20USD
11:19am EDT
Change (% chg)

$0.11 (+0.33%)
Prev Close
$33.09
Open
$33.16
Day's High
$33.21
Day's Low
$33.05
Volume
5,205,111
Avg. Vol
2,962,482
52-wk High
$35.40
52-wk Low
$17.61

AKRX.O

Chart for AKRX.O

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $4,118.04
Shares Outstanding(Mil.): 124.45
Dividend: --
Yield (%): --

Financials

  AKRX.O Industry Sector
P/E (TTM): 22.47 29.33 30.27
EPS (TTM): 1.47 -- --
ROI: 10.21 13.69 13.24
ROE: 25.58 14.64 14.40

Deals of the day-Mergers and acquisitions

April 25 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Apr 25 2017

Fresenius picks up M&A pace with Akorn, Merck KGaA deals

FRANKFURT German healthcare group Fresenius SE & Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA.

Apr 25 2017

UPDATE 2-Fresenius picks up M&A pace with Akorn, Merck KGaA deals

* Fresenius shares up almost 1 percent (Adds advisers, shares, background, CEO, analyst comments)

Apr 25 2017

German stocks - Factors to watch on April 25

FRANKFURT, April 25 The DAX top-30 index looked set to open 0.3 percent higher on Tuesday, according to premarket data from brokerage Lang & Schwarz at 0625 GMT.

Apr 25 2017

BRIEF-Akorn deal to pay Fresenius Kabi AG termination fee of $129 mln under specified circumstances

* Akorn - deal with Fresenius Kabi provides under specified circumstances, co to be required to pay Fresenius Kabi AG termination fee of $129 million Source text: (http://bit.ly/2oEMWQV) Further company coverage:

Apr 24 2017

Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals

FRANKFURT, April 24 Acquisitive German healthcare conglomerate Fresenius SE & Co KGaA revved up its deals pace by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros), and in a separate deal, the biosimilars unit of German peer Merck KGaA .

Apr 24 2017

Exclusive: Fresenius nears deal to acquire Akorn - sources

German healthcare conglomerate Fresenius SE & Co KGaA is close to acquiring generic drugmaker Akorn Inc in an all-cash deal valuing the company at more than $4 billion, people familiar with the matter said on Monday.

Apr 24 2017

Akorn hit with $20.5 million verdict over failure to warn

Generic drugmaker Akorn Inc must pay $20.5 million in a lawsuit by a Georgia teacher who accused the company of failing to warn that one of its products would react adversely with another medication she was already taking, a state court jury has ruled.

Apr 11 2017

German stocks - Factors to watch on April 10

FRANKFURT/BERLIN, April 10 The DAX top-30 index looked set to open 0.2 percent higher on Monday, according to premarket data from brokerage Lang & Schwarz at 0608 GMT.

Apr 10 2017

Germany's Fresenius in talks to buy generic drugmaker Akorn

German healthcare group Fresenius SE & Co KGaA said on Friday that it was in talks with the generic drugmaker Akorn Inc for a potential takeover.

Apr 07 2017

More From Around the Web

Earnings vs. Estimates